Format

Send to

Choose Destination
Emerg Infect Dis. 2004 Apr;10(4):581-6.

Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs.

Author information

1
Genome Institute of Singapore, Singapore.

Abstract

Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti-SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors. Complete inhibition of cytopathic effects of SARS-CoV in culture was observed for interferon subtypes, b-1b, a-n1, a-n3, and human leukocyte interferon a. These findings support clinical testing of approved interferons for the treatment of SARS.

PMID:
15200845
PMCID:
PMC3323075
DOI:
10.3201/eid1004.030458
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for CDC-NCEZID Icon for PubMed Central
Loading ...
Support Center